HK1210154A1 - Highly selective c-met inhibitors as anticancer agents c-met - Google Patents

Highly selective c-met inhibitors as anticancer agents c-met

Info

Publication number
HK1210154A1
HK1210154A1 HK15110897.6A HK15110897A HK1210154A1 HK 1210154 A1 HK1210154 A1 HK 1210154A1 HK 15110897 A HK15110897 A HK 15110897A HK 1210154 A1 HK1210154 A1 HK 1210154A1
Authority
HK
Hong Kong
Prior art keywords
met
anticancer agents
highly selective
inhibitors
met inhibitors
Prior art date
Application number
HK15110897.6A
Other languages
English (en)
Chinese (zh)
Inventor
Boyu Zhong
Chuan Shih
Hongbin Yuan
Feng Zhou
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Publication of HK1210154A1 publication Critical patent/HK1210154A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15110897.6A 2012-09-03 2015-11-04 Highly selective c-met inhibitors as anticancer agents c-met HK1210154A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012103223591A CN103122000B (zh) 2012-09-03 2012-09-03 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
PCT/CN2013/080598 WO2014032498A1 (en) 2012-09-03 2013-08-01 Highly selective c-met inhibitors as anticancer agents

Publications (1)

Publication Number Publication Date
HK1210154A1 true HK1210154A1 (en) 2016-04-15

Family

ID=48453178

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110897.6A HK1210154A1 (en) 2012-09-03 2015-11-04 Highly selective c-met inhibitors as anticancer agents c-met

Country Status (6)

Country Link
US (1) US9695175B2 (ja)
EP (1) EP2892904B1 (ja)
JP (1) JP6106899B2 (ja)
CN (1) CN103122000B (ja)
HK (1) HK1210154A1 (ja)
WO (1) WO2014032498A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105326793A (zh) * 2014-08-06 2016-02-17 中美冠科生物技术（太仓）有限公司 一种包含c-Met激酶抑制剂的固体分散体及其制备方法和用途
CN108853108A (zh) 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN109206357A (zh) * 2017-07-04 2019-01-15 浙江九洲药业股份有限公司 一种格列齐特中间体的通式化合物及其制备方法和应用
EP3752528A4 (en) * 2018-02-17 2021-11-03 Apollomics Inc. CANCER TREATMENT USING A COMBINATION OF A NEUTROPHIL MODULATOR WITH AN IMMUNE CHECKPOINT MODULATOR
AU2019395282A1 (en) * 2018-12-14 2021-07-08 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN114599978A (zh) * 2019-06-06 2022-06-07 浙江冠科美博生物科技有限公司 使用c-met抑制剂治疗癌症患者的方法
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230338294A1 (en) * 2020-04-26 2023-10-26 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
CN113105436B (zh) * 2021-04-20 2022-07-01 西格莱(苏州)生物医药有限公司 吡唑类化合物的制备方法及其中间体
WO2024068947A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2024068950A1 (en) 2022-09-30 2024-04-04 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
CN116854694A (zh) * 2023-07-04 2023-10-10 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030305B2 (en) 2005-12-21 2011-10-04 Janssen Pharmaceutica N.V. Triazolopyridazines as kinase modulators
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
JP2010507577A (ja) * 2006-10-23 2010-03-11 エスジーエックス ファーマシューティカルズ、インコーポレイテッド トリアゾロピリダジンタンパク質キナーゼモジュレーター
CN101558070A (zh) * 2006-10-23 2009-10-14 Sgx药品公司 三唑并哒嗪蛋白激酶调节剂
AU2007309149C1 (en) * 2006-10-23 2013-04-04 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
BRPI0908504A2 (pt) * 2008-02-28 2015-08-11 Novatis Ag Compostos derivados de 3-metil-imidazo[1,2-b]piridazina, uso dos mesmos e composição farmacêutica
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer

Also Published As

Publication number Publication date
WO2014032498A1 (en) 2014-03-06
JP6106899B2 (ja) 2017-04-05
US20150218171A1 (en) 2015-08-06
CN103122000A (zh) 2013-05-29
US9695175B2 (en) 2017-07-04
JP2015526486A (ja) 2015-09-10
EP2892904A4 (en) 2016-04-06
EP2892904B1 (en) 2018-10-17
CN103122000B (zh) 2013-12-25
EP2892904A1 (en) 2015-07-15

Similar Documents

Publication Publication Date Title
HRP20181849T1 (hr) Triciklični spojevi kao antikancerogeni agensi
HK1210154A1 (en) Highly selective c-met inhibitors as anticancer agents c-met
HK1212984A1 (zh) 咪唑並吡啶化合物
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
EP2823830A4 (en) MESH-HIGHNESS MEDIUM
EP2864289A4 (en) CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS USEFUL AS ANTI-TUMOR AGENTS
HK1202859A1 (en) Anti -malarial agents
HK1203811A1 (en) Anticancer agent
EP2842561A4 (en) MEANS FOR OPTIMIZING THE ENTERAL ENVIRONMENT
ZA201408094B (en) Anti-malarial agents
EP2804611A4 (en) COMPOSITIONS FROM CHITOSAN
GB201201287D0 (en) Compositions
EP2837387A4 (en) ANTICANCER AGENT
EP2889035A4 (en) ANTI-TUMOR AGENT
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
HUE045654T2 (hu) Anyagkeverékek
ZA201400726B (en) Anticancer agent
RS55201B1 (sr) Antimalarijski agensi
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS
GB201208751D0 (en) Anti-malarial compounds
GB201203082D0 (en) Compositions
GB201203083D0 (en) Compositions